Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Evofem Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$472.00K. For fiscal 2025 it was -$1.99M. The highest annual figure on record is -$1.99M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.99M | – |
| FY2024 | Dec 31, 2024 | -$3.89M | – |
| FY2023 | Dec 31, 2023 | -$8.97M | – |
| FY2022 | Dec 31, 2022 | -$70.41M | – |
| FY2021 | Dec 31, 2021 | -$146.67M | – |
| FY2020 | Dec 31, 2020 | -$104.83M | – |
| FY2019 | Dec 31, 2019 | -$55.10M | – |
| FY2018 | Dec 31, 2018 | -$56.50M | – |
| FY2017 | Dec 31, 2017 | -$19.24M | – |
| FY2016 | Dec 31, 2016 | -$16.25M | – |
| FY2015 | Dec 31, 2015 | -$37.91M | – |
| FY2014 | Dec 31, 2014 | -$9.57M | – |
| FY2013 | Dec 31, 2013 | -$12.90M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.14M | – |
| Q1 FY2026 | Mar 31, 2026 | $2.30M | +310.9% |
| Q4 FY2025 | Dec 31, 2025 | $31.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $336.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.92M | – |
| Q1 FY2025 | Mar 31, 2025 | $560.00K | +355.3% |
| Q4 FY2024 | Dec 31, 2024 | -$2.41M | – |
| Q3 FY2024 | Sep 30, 2024 | -$459.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.14M | – |
| Q1 FY2024 | Mar 31, 2024 | $123.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.49M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.53M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.66M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.92M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$37.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$53.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$34.46M | – |
| Q4 FY2020 | Dec 31, 2020 | -$39.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$35.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.05M | – |
| Q1 FY2020 | Mar 31, 2020 | -$14.88M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.45M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.43M | – |
| Q2 FY2019 | Jun 30, 2019 | -$19.55M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.68M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.25M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.19M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.14M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.95M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.75M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.47M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.07M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.89M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.12M | – |
| Q2 FY2016 | Jun 30, 2016 | -$2.64M | – |
See a number that looks wrong?